Madison Muller, Bloomberg News health reporter, says that the failure of a long-shot trial to see if the pill form of Novo Nordisk’s weight loss drug Ozempic impacted Alzheimer’s was the latest in a long string of disappointments for investors into the pharmaceutical company. Novo Nordisk is down over 50% on the year. (Source: Bloomberg)
https://www.bloomberg.com/news/videos/2025-11-24/novo-shares-drop-as-ozempic-pill-fails-alzheimer-s-trial-video
Novo Shares Drop as Ozempic Pill Fails Alzheimer’s Trial
